The Enhancement Gap Is Now a Health Divide, Not Just a Wealth One

GENEVA — The number that unsettled the room at the Alpine Geneva Polytechnic symposium was not a price but a probability. When roughly one in twenty people carries somatic augmentation that pushes healthy life past a hundred, the insurers who pool everyone's risk together find the pool has split beneath them. "We used to sell longevity as a luxury good," said one actuary who asked to be named only as working for a mid-tier health mutual. "Now it is a fork in the mortality curve, and the fork runs through families." The unaugmented are not merely poorer, she explained; they are, in the cold language of the tables, a different population — one whose premiums quietly subsidize a divergence they cannot afford to join. Clinicians report the divide showing up in ordinary medicine: augmented patients metabolizing drugs differently, healing faster, aging along a track standard protocols were never written for. The century promised that enhancement was a personal choice. The ledgers now suggest it is a collective condition, and one the health system was never designed to hold in two halves at once.